CFDA Said Considering Shortening Oncology Drug INDs To 60 Days
This article was originally published in PharmAsia News
Executive Summary
In one reform after another, the China FDA is acting swiftly to accelerate new drug approvals, this time with a focus on innovative cancer therapies. The agency is said to be planning a pilot scheme that would change the current investigational new drug (IND) process from an approval to a filing mechanism, and set 60 days as the timeframe.